Table 3. Multivariate analysis of outcome predictors.
| Prognostic marker | Stage II (n = 66) |
Stage III (n = 79) |
Stage II/III (n = 145) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| DFS | P | Hazard Ratio | 95% CI | P | Hazard Ratio | 95% CI | P | Hazard Ratio | 95% CI |
| Sex | 0.978 | 278790.681 | 0.0001 to ∞ | 0.464 | 1.701 | 0.411 to7.0 | 0.352 | 1.869 | 0.501 to 9.0 |
| Age | 0.419 | 2.729 | 0.239 to 31.2 | 0.152 | 3.199 | 0.652 to 15.7 | 0.069 | 3.305 | 0.91 to 12.0 |
| Tumor differentiation | 0.217 | 5.049 | 0.386 to 66.1 | 0.022 | 3.879 | 1.215 to 12.4 | 0.007 | 4.264 | 1.486 to 12.2 |
| Nodal stage | – | – | – | 0.895 | 1.086 | 0.317 to 3.7 | 0.142 | 1.675 | 0.841 to 3.3 |
| KRAS mutation | 0.542 | 2.234 | 0.169 to 29.5 | 0.372 | 0.543 | 0.142 to 2.1 | 0.702 | 0.807 | 0.269 to 2.4 |
| BRAF mutation | 0.990 | <0.0001 | 0.0001 to ∞ | 0.927 | 1.103 | 0.136 to 8.9 | 0.762 | 0.729 | 0.094 to 5.7 |
| PIK3CA mutation | 0.964 | <0.0001 | 0.0001 to ∞ | 0.383 | 0.461 | 0.081 to 2.6 | 0.368 | 0.48 | 0.097 to 2.4 |
| OS | |||||||||
| Sex | 0.978 | 285332.546 | 0.0001 to ∞ | 0.462 | 1.697 | 0.415 to 6.9 | 0.339 | 1.904 | 0.508 to 7.1 |
| Age | 0.454 | 2.537 | 0.222 to 28.9 | 0.112 | 3.623 | 0.742 to 17.7 | 0.050 | 3.59 | 0.98 to 12.9 |
| Tumor differentiation | 0.190 | 5.486 | 0.429 to 70.1 | 0.029 | 3.642 | 1.14 to 11.6 | 0.006 | 4.358 | 1.526 to 12.4 |
| Nodal stage | – | – | – | 0.934 | 1.054 | 0.305 to 3.6 | 0.170 | 1.618 | 0.813 to 3.2 |
| KRAS mutation | 0.540 | 2.234 | 0.171 to 29.2 | 0.334 | 0.514 | 0.133 to 2.0 | 0.567 | 0.725 | 0.24 to 2.2 |
| BRAF mutation | 0.990 | <0.0001 | 0.0001 to ∞ | 0.992 | 0.989 | 0.121 to 8.1 | 0.652 | 0.622 | 0.079 to 4.9 |
| PIK3CA mutation | 0.963 | <0.0001 | 0.0001 to ∞ | 0.430 | 0.496 | 0.087 to 2.8 | 0.427 | 0.523 | 0.105 to 2.6 |